Canaccord Genuity Maintains a 'Buy' on DexCom (DXCM); Gen 4 in FDA's Hands Now
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $92.34 +2.35%
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on DexCom (NASDAQ: DXCM) price target of $11.50.
Analyst, William J. Plovanic, said, "We maintain our rating following DexCom’s expectation-matching results and management reaffirming guidance. DexCom also announced that the PMA submission for the Gen 4 sensor was filed with the FDA in Q1/12. Net, net we believe Q1/12 was a solid quarter with typical Q1 seasonality preventing outperformance. We note that FDA submissions for sensor augmented pump PMAs have been delayed until Gen 4 is approved, which may surprise investors. However, our timelines remain unaffected given our conservative stance regarding any regulatory timelines."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $10.11 yesterday.
Analyst, William J. Plovanic, said, "We maintain our rating following DexCom’s expectation-matching results and management reaffirming guidance. DexCom also announced that the PMA submission for the Gen 4 sensor was filed with the FDA in Q1/12. Net, net we believe Q1/12 was a solid quarter with typical Q1 seasonality preventing outperformance. We note that FDA submissions for sensor augmented pump PMAs have been delayed until Gen 4 is approved, which may surprise investors. However, our timelines remain unaffected given our conservative stance regarding any regulatory timelines."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $10.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
